Liquidia Technologies
  |   |   |
   Home  |  Site Map  |  Contact Us  


Management Team
Board of Directors

Board of Directors

Seth Rudnick, M.D. - Chairman
Dr. Seth Rudnick is an adjunct Clinical Professor of Medicine at The University of North Carolina-Chapel Hill (UNC-CH) and is a Partner at Canaan Partners, a global venture capital firm. He is well known for his expertise in healthcare investments and has worked closely with numerous companies to develop novel therapeutic products. In 2006 and 2007, Dr. Rudnick was named to the Forbes Midas List, a ranking of the top venture capitalists in technology and life sciences. Prior to joining Canaan Partners, Dr. Rudnick served as CEO and Chairman of CytoTherapeutics and previously led research and development for Ortho Biotech, a Johnson & Johnson subsidiary. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania.

Neal Fowler - Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Neal served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in both the pharmaceutical and medical divisions. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill (UNC-CH).

Stephen Bloch, M.D.
Dr. Stephen Bloch is a General Partner at Canaan Partners where he is focused on investments in biopharmaceuticals, medical devices and diagnostics, and healthcare infrastructure. Prior to joining Canaan in 2002, Stephen founded Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services, where he was CEO for six years. After founding RMS, Stephen helped start and served as medical director of OmniSonics Medical Technologies, which is commercializing novel ultrasonic devices to treat vascular occlusive disease. He also co-founded TeleRad, a teleradiology services company. Dr. Bloch started his career as a practicing radiologist and received his medical training at Massachusetts General Hospital/Harvard Medical School and Lenox Hill Hospital/Cornell Medical School.

Isaac Cheng, M.D.
Dr. Cheng of Morningside Technology Advisory LLC focuses on life science and technology investments. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi in the Genetics and Aging Unit of the Massachusetts General Hospital / Harvard Medical School. He has worked with many start ups and currently sits on the Board of Directors of Traversa Therapeutics and is a board observer to Argos Therapeutics.

Ed Mathers
Mr. Mathers joined NEA as a partner in August 2008 after a successful 26 years in the biopharm industry. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc, where he was responsible for leading the company's venture capital subsidiary, and all business and corporate development activities. In addition, Mr. Mathers was an integral member of the executive team that led to the sale of MedImmune to Astra Zeneca in 2007. Prior to joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in a variety of commercial roles, and started his career at Ortho Pharmaceuticals Corporation, an operating company of Johnson & Johnson. Mr. Mathers currently sits on the Boards of Directors of Intarcia Therapeutics, Inc., Satori Therapeutics and Plexxikon Inc. He earned his bachelor's degree in chemistry from North Carolina State University.

Ralph Snyderman, M.D.
Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. Dr. Snyderman served as Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to July 2004. He also oversaw the development of the Duke University Health System where he served as its first President and Chief Executive Officer. Dr. Snyderman is also a Venture Partner at New Enterprise Associates (NEA) where he focuses primarily on biotechnology investments. Previously, Snyderman was Senior Vice President for Medical Research and Development at Genentech, Inc. He played a prominent role in the leadership of such important national organizations as the Association of American Physicians, the Institute of Medicine and the Association of American Medical Colleges. Dr. Snyderman is the recipient of numerous prestigious awards and honors as well as a major contributor to nearly 400 scientific manuscripts.

© 2015 Liquidia Technologies | PO Box 110085 | Research Triangle Park, NC 27709 | P.919.328.4400 | F.919.328.4402 | email: